US2014187781A1PendingUtilityA1
Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
Est. expiryNov 2, 2026(~0.3 yrs left)· nominal 20-yr term from priority
A61P 9/10A61P 35/02A61P 37/00A61P 35/00A61P 3/10A61P 5/00A61P 9/00A61P 37/06A61P 43/00A61P 37/04A61P 9/04A61P 25/16A61P 25/24A61P 25/00A61P 25/28A61P 3/00A61P 25/18A61P 25/14A61P 29/00C07D 417/12A61P 21/02A61P 19/02A61P 19/08C07D 471/04C07D 403/14A61P 17/06C07D 403/12A61P 11/06C07D 417/14A61P 19/10
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
Ht is
Ring D is a 5-7 membered monocyclic aryl or heteroaryl ring, said heteroaryl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur; wherein said Ring D has one or two ortho substituents independently selected from —R 1 ; any substitutable non-ortho carbon position on Ring D is independently substituted with —R 5 , and two adjacent substituents on Ring D are optionally taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, said fused ring being optionally substituted with halo, oxo, or —R 8 ;
R 1 is selected from -halo, —CN, —NO 2 , T-V—R 6 , phenyl, 5-6 membered heteroaryl ring, 4-6 membered heterocyclyl ring, or a C 1-6 aliphatic group; wherein said phenyl, heteroaryl, and heterocyclyl ring is each optionally substituted with up to three groups independently selected from halo, oxo, or —R 8 ; and wherein said C 1-6 aliphatic group is optionally substituted with halo, cyano, nitro, OH or oxo; or R 1 and an adjacent substituent taken together with their intervening atoms form said ring fused to Ring D;
X is sulfur, oxygen, or NR 2′ ;
Y is nitrogen or CR 2 ;
one of Z 1 and Z 2 is nitrogen and one of Z 1 or Z 2 is CR 9 ;
R X is -T 1 -R 3 ;
R Y is -T 2 -R 10 ;
R 2 and R 2′ are independently selected from —R or -T 3 -W—R 6 ; or R 2 and R 2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur; wherein each substitutable carbon on said fused ring formed by R 2 and R 2′ is substituted with halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and any substitutable nitrogen on said ring formed by R 2 and R 2′ is substituted with R 4 ;
each T, T 1 and T 3 is a bond or a C 1-4 alkylidene chain;
T 2 is independently a bond or a C 1-4 alkylidene chain wherein up to three methylene units of the alkylidene chain are optionally replaced by —O—, —C(C═O)—, —S(O)—, —S(O) 2 —, —S—, or —N(R 4 )—;
R 3 is selected from —R, -halo, —OR, —C(═O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC(═O)R, —N(R 7 )COR, —N(R 7 )CO 2 R″, —N(R 4 )N(R 4 ) 2 , —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC(═O)N(R 7 ) 2 ;
each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 R″, —CON(R 7 ) 2 , or —SO 2 R 7 , or two R 4 on the same nitrogen are taken together to form a 3-8 membered heterocyclyl or heteroaryl ring;
each R 5 is independently selected from —R, halo, —OR, —C(═O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC(═O)R, —N(R 4 )COR, —N(R 4 )CO 2 R″, —N(R 4 )N(R 4 ) 2 , —C═NN(R 4 ) 2 , —C═N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC(═O)N(R 4 ) 2 ;
V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )C(O)—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 )═NN(R 6 )—, —C(R 6 )═N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 ) 2 N(R 6 )SO 2 N(R 6 )—, or —C(R 6 ) 2 N(R 6 )CON(R 6 )—;
W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 ) 2 OC(O)—, —C(R 6 ) 2 OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 )═NN(R 6 )—, —C(R 6 )═N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 ) 2 N(R 6 )SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )CON(R 6 )—, or —CON(R 6 )—;
each R 6 is independently selected from hydrogen or C 1-4 aliphatic group optionally substituted with 0-3 J 6 ; or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 4-6 membered heterocyclyl or heteroaryl ring, wherein said heterocyclyl or heteroaryl ring is optionally substituted with 0-4 J 6 ;
each R 7 is independently selected from hydrogen or R″; or two R 7 on the same nitrogen are taken together with the nitrogen to form a 4-8 membered heterocyclyl or heteroaryl ring, wherein said heterocyclyl or heteroaryl ring is optionally substituted with 0-4 J 7 ;
each R 8 is independently selected from —OR 6 , —SR 6 , —COR 6 , —SO 2 R 6 , —N(R 6 ) 2 , —N(R 6 )N(R 6 ) 2 , —CN, —NO 2 , —CON(R 6 ) 2 , —CO 2 R 6 , or a C 1-4 aliphatic group, wherein said C 1-4 aliphatic group is optionally substituted with 0-3 J 8 ;
each R 9 is —R′, -halo, —OR′, —C(C═O)R′, —CO 2 R′, —COCOR′, COCH 2 COR′, —NO 2 , —CN, —S(O)R′, —S(O) 2 R′, —SR′, —N(R′) 2 , —CON(R′) 2 , —SO 2 N(R′) 2 , —OC(═O)R′, —N(R′)COR′, —N(R′)CO 2 (C 1-6 aliphatic), —N(R′)N(R′) 2 , —N(R′)CON(R′) 2 , —N(R′)SO 2 N(R′) 2 , —N(R′)SO 2 R′, —OC(═O)N(R′) 2 , ═NN(R′) 2 , ═N—OR′, or ═O;
each R 10 is a 4-membered heterocyclic ring containing 1-2 heteroatoms selected from O, NR 11 , or S; each R 10 is optionally substituted with 0-6 occurrences of J;
each R 11 is —R 7 , —COR 7 , —CO 2 R″, —CON(R 7 ) 2 , or —SO 2 R 7 ;
each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 4-10 ring atoms; each R is optionally substituted with 0-5 R 9 ;
each R′ is independently hydrogen or a C 1-6 aliphatic group optionally substituted with 0-4 J′; or two R′, together with the atom(s) to which they are attached, form a 3-6 membered carbocyclyl or heterocyclyl wherein said carbocyclyl or heterocyclyl is optionally substituted with 0-4 J′;
each R″ is independently C 1-6 aliphatic optionally substituted with 0-4 J″;
each J′ and J″ is independently NH 2 , NH(C 1-4 aliphatic), N(C 1-4 aliphatic) 2 , halogen, C 1-4 aliphatic, OH, O(C 1-4 aliphatic), NO 2 , CN, CO 2 H, CO 2 (C 1-4 aliphatic), O(haloC 1-4 aliphatic), or haloC 1-4 aliphatic;
each J, J 6 , and J 8 is independently -halo, —OR, oxo, C 1-6 aliphatic, —C(C═O)R, —CO 2 R, —COCOR, COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 )2, —OC(═O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , ═NN(R 4 ) 2 , ═N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC(═O)N(R 7 ) 2 ;
each J 7 is independently -halo, —OR, oxo, C 1-6 aliphatic, —C(═O)R, —CO 2 R, —COCOR, COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 22 ) 2 , —CON(R 22 ) 2 , —SO 2 N(R 22 ) 2 , —OC(═O)R, —N(R 22 )COR, —N(R 22 )CO 2 (C 2-6 aliphatic), —N(R 22 )N(R 12 ) 2 , ═NN(R 22 ) 2 , ═N—OR, —N(R 22 )CON(R 22 ) 2 , —N(R 22 )SO 2 N(R 22 ) 2 , —N(R 22 )SO 2 R, or —OC(═O)N(R 22 ) 2 ; or
2 J groups, 2 J 6 groups, 2 J 2 groups, or 2 J 8 groups, on the same atom or on different atoms, together with the atom(s) to which they are bound, form a 3-8 membered saturated, partially saturated, or unsaturated ring having 0-2 heteroatoms selected from O, N, or S;
R 12 is independently selected from hydrogen or R″; or two R 12 on the same nitrogen are taken together with the nitrogen to form a 4-8 membered heterocyclyl or heteroaryl ring, wherein said heterocyclyl or heteroaryl ring is optionally substituted with 0-4 J″.
2 . The compound according to claim 1 wherein Ht is
3 . The compound according to claim 1 wherein Ht is
4 . The compound according to claim 3 , wherein X is S.
5 . The compound according to claim 4 , wherein Y is N.
6 . The compound according to claim 4 , wherein Y is CR 2 .
7 - 16 . (canceled)
17 . The compound according to claim 1 , wherein R X is hydrogen, C 1-4 aliphatic, or halo.
18 . The compound according to claim 17 , wherein R X is hydrogen, fluoro, methyl, or ethyl.
19 . The compound according to claim 18 , wherein R X is hydrogen.
20 . The compound according to claim 1 , wherein R Y is represented by formula ii-a:
21 . The compound according to claim 1 , wherein R Y is T 2 -R 10 wherein T 2 is a bond.
22 . The compound according to claim 21 , wherein R 10 is an optionally substituted azetidine.
23 . The compound according to claim 22 , wherein R Y is represented by formula i:
24 . The compound according to claim 22 , wherein R Y is represented by formula iii:
25 . The compound according to claim 1 , wherein Ring D is an optionally substituted ring selected from phenyl, pyridinyl, quinolinyl, or naphthyl.
26 . The compound according to claim 1 , wherein Ring D is phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring.
27 . The compound according to claim 26 , wherein Ring D is phenyl or pyridinyl.
28 . The compound according to claim 1 , wherein Ring D is optionally substituted phenyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrazinyl, naphthyl, benzimidazolyl, benzthiazolyl, quinolinyl, quinazolinyl, isobenzofuran, indolyl, or indazolyl.
29 . (canceled)
30 . The compound according to claim 1 , wherein R 1 is -halo, a C 1-6 haloaliphatic group, an optionally substituted C 1-6 aliphatic group, phenyl, or —CN.
31 . The compound according to claim 30 , wherein R 1 is -halo, a C 1-4 aliphatic group optionally substituted with halogen, or —CN.
32 - 43 . (canceled)Join the waitlist — get patent alerts
Track US2014187781A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.